![]() Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Investors should take the time to consider JAZZ for their portfolios due to its solid Zacks Ranks, notable earnings and valuation metrics, and impressive Value and VGM Style Scores. JAZZ has an average earnings surprise of 12.8%. The Zacks Consensus Estimate has increased $0.57 to $17.05 per share. 11 analysts revised their earnings estimate upwards in the last 60 days for fiscal 2022. ![]() Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. ![]() Shares of Jazz Pharmaceuticals are trading at a forward earnings multiple of 8.8X, as well as a PEG Ratio of 1.1, a Price/Cash Flow ratio of 6.5X, and a Price/Sales ratio of 2.8X. JAZZ boasts a Value Style Score of A and VGM Score of A, and holds a Zacks Rank #3 (Hold) rating. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. Common Stock (SXTP) stock quote, history, news and other vital information to help you with your stock trading and investing. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem. Find the latest 60 Degrees Pharmaceuticals, Inc. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, and Price/Cash Flow to help pick out the most attractive and discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Different than growth or momentum investors, value-focused investors are all about finding good stocks at good prices, and discovering which companies are trading under what their true value is before the broader market catches on. ![]() The company has licensing and collaboration agreements with ImmunoGen, Inc. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients JZP385, a T-type calcium channel modulator, for the treatment of essential tremor JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients and JZP150 for treatment of post-traumatic stress disorder. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea Erwinaze to treat acute lymphoblastic leukemia Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders and in oncology, including hematologic and solid tumors. Short of Shares Outstanding (May 31, 2023) 4, 4.88. Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. Find out all the key statistics for Jazz Pharmaceuticals plc (JAZZ), including valuation measures. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |